On April 14, 2011, Nakao, Akira; Suzuki, Hiroko; Tatsumi, Ryo; Setsuta, Tomofumi; Seki, Maki; Iwasaki, Hiroshi; Zheng, Zhongli; Makara, Gergely; Dai, Chaoyang; Siddiqui, Arshad; Kawahata, Noriyuki; Nan, Yang published a patent.Computed Properties of 34662-29-8 The title of the patent was Preparation of bis(glycinamide) derivatives as homocysteine synthase inhibitors. And the patent contained the following:
There are disclosed homocysteine synthase inhibitors which are useful for the prevention or treatment of diseases associated with a homocysteine synthase, e.g. arteriosclerosis, cerebral infarction, or myocardial infarction. There are specifically disclosed N-(carbamoylmethyl)glycinamide compounds represented by general formula [I; R1 = H, C1-3 alkyl; R2 = (un)substituted heterocyclyl containing at least one N atom in the ring, NR2aR2b; R2a, R2b = H, C1-6 alkyl, haloalkyl, (un)substituted aryl; R3 = H; R4, R5, R6, R7 = H, C1-4 alkyl; L = [C(R8a)(R8b)]s[C(R8c)(R8d)]t; s, t = an integer of 0-2; R8a, R8b, R8c, R8d = H, C1-3 alkyl; Ar = l = an integer of 0-4; X = O, S; R9 = each (un)substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, heterocyclyl, aryl, heteroaryl, or arylalkyl; R10 = halo, cyano, C1-6 alkyl, CF3, HO, C1-4 alkoxy, CF3O, COR12, each (un)substituted NH2, aryl, heteroaryl, heterocyclyl, C1-6 alkyl-S(O)m; R12 = HO, C1-6 alkyl, C1-6 alkoxy, (un)substituted NH2; m = an integer of 0-2; A = each (un)substituted aryl, aryl-C1-4 alkyl, heteroaryl-C1-4 alkyl, C3-6 alkynyl, or C3-8 cycloalkyl, Q1, Q2, etc.; n = an integer of 0-2; h = 0, 1; i = 1, 2; R14 = C1-4 alkyl, W = :CH, :N], pharmacol. acceptable salts of the compounds, or solvates of the compounds or the pharmacol. acceptable salts. Thus, N-[5-chloro-2-(4-chlorophenoxy)phenyl]-N-[2-[(1,3-dihydro-2H-isoindol-2-yl)(methyl)amino]-2-oxoethyl]glycine 412, tert-Bu (2-aminoethyl)methylcarbamate hydrochloride 270, and 1-hydroxybenzotriazole 181 mg were dissolved in 1 mL DMF and 10 mL CH2Cl2, treated with 265 mg 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, and stirred at room temperature for 3 h to give, after workup and silica gel chromatog., 75% N’-[5-chloro-2-(4-chlorophenoxy)phenyl]-N’-[2-[(1,3-dihydro-2H-isoindol-2-yl)(methyl)amino]-2-oxoethyl]-N-[2-[(tert-butoxycarbonyl)(methyl)amino]ethyl]glycinamide (II) (407 mg). II (387 mg) was dissolved in 2 mL CH2Cl2, treated with 2.0 mL 4 N HCl/dioxane solution at room temperature, and stirred at room temperature for 90 min, and treated with Et2O for precipitation of a solid which was filtered off and dried under reduced pressure to give 64% N’-[5-chloro-2-(4-chlorophenoxy)phenyl]-N’-[2-[(1,3-dihydro-2H-isoindol-2-yl)(methyl)amino]-2-oxoethyl]-N-[2-(methylamino)ethyl]glycinamide (III) dihydrochloride. III.2HCl in vitro showed IC50 of 2.6 nM for inhibiting the hydrolysis of S-adenosyl-L-homocysteine by human recombinant S-adenosyl-L-homocysteine hydrolase. The experimental process involved the reaction of 3-Chloro-4-nitrobenzonitrile(cas: 34662-29-8).Computed Properties of 34662-29-8
The Article related to bisglycinamide derivative preparation homocysteine synthase inhibitor, carbamoylmethylglycinamide preparation homocysteine synthase inhibitor, adenosyl homocysteine hydrolase inhibitor bisglycinamide derivative preparation, arteriosclerosis cerebral infarction myocardial infarction prevention treatment bisglycinamide preparation and other aspects.Computed Properties of 34662-29-8
Referemce:
Nitrile – Wikipedia,
Nitriles – Chemistry LibreTexts